feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

trending

Vedanta demerger gets final nod

trending

Chennai weather: heavy rain alert

trending

POCO M8 5G launch

trending

Rishabh Pant ruled out

trending

Kohli nears Tendulkar's record

trending

Nigeria beats Algeria in AFCON

trending

India vs New Zealand ODI

trending

Chelsea beats Charlton 5-1

trending

Sixers vs Hurricanes BBL match

Home / Health / Nimesulide Ban: India Re-evaluates Painkiller Risks

Nimesulide Ban: India Re-evaluates Painkiller Risks

10 Jan

•

Summary

  • Nimesulide offered quick pain relief but posed significant liver risks.
  • Studies link high doses and prolonged use to severe liver damage.
  • Several European countries banned Nimesulide years ago due to side effects.
Nimesulide Ban: India Re-evaluates Painkiller Risks

Nimesulide, a painkiller popular in India for its rapid effectiveness, is facing renewed attention due to its safety profile. While widely used for fever and pain, emerging evidence over decades highlights risks associated with high dosages and extended treatment periods. Concerns about hepatotoxicity, including liver damage and failure, have led to regulatory actions.

Studies have indicated a significant risk of acute liver injury within 30 days of use, with some cases requiring transplantation or proving fatal. These findings prompted bans in European nations like Finland and Spain as early as 2002, followed by Ireland, Malaysia, Singapore, Vietnam, and Argentina in subsequent years.

Health professionals now advise patients on Nimesulide to consult healthcare providers for immediate discontinuation. Alternative pain management strategies, including physiotherapy, lifestyle adjustments, and other NSAIDs like ibuprofen or diclofenac at approved doses, are being promoted as safer options.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Nimesulide can cause serious liver damage, including liver failure, especially with high doses or prolonged use.
Several European countries like Finland, Spain, and Ireland, along with Malaysia, Singapore, Vietnam, and Argentina, have banned Nimesulide.
Safer alternatives include physiotherapy, lifestyle changes, paracetamol, ibuprofen, and diclofenac at approved doses.

Read more news on

Indiaside-arrowHealthside-arrowSpainside-arrowSingaporeside-arrowFinlandside-arrowMalaysiaside-arrow

You may also like

India's Weight-Loss Drug Boom: Patient Willingness Drives Market

3 Jan • 66 reads

article image

New Pill Boosts Fat Burning Without Muscle Loss

10 Dec, 2025 • 154 reads

article image

Cheap Thrills, Deadly Cost: Methanol Kills Global Tourists

29 Nov, 2025 • 361 reads

article image

Cop30 Fails Climate Ambition: Aid Delays, Fossil Fuels Unchecked

23 Nov, 2025 • 306 reads

article image

Medtronic and Minze Health Collaborate to Advance Bladder Care Across EMEA Region

13 Nov, 2025 • 134 reads